tradingkey.logo

Predictive Oncology Inc

POAI
View Detailed Chart

1.010USD

+0.023+2.31%
Close 09/19, 16:00ETQuotes delayed by 15 min
9.69MMarket Cap
LossP/E TTM

Predictive Oncology Inc

1.010

+0.023+2.31%
Intraday
1m
30m
1h
D
W
M
D

Today

+2.31%

5 Days

+6.32%

1 Month

+12.22%

6 Months

-10.62%

Year to Date

+23.17%

1 Year

+14.76%

View Detailed Chart

TradingKey Stock Score

Currency: USD Updated: 2025-09-19

Key Insights

The company's fundamentals are relatively stable. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a . The company shows weak stock market performance, in line with its weak fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking
290 / 506
Overall Ranking
495 / 4720
Industry
Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score
Previous score

Analyst Rating

Based on 0 analysts
--
Current Rating
3.000
Target Price
+251.62%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks
Predictive Oncology Inc. is a knowledge-driven company focused on applying artificial intelligence (AI) to support the development of cancer therapies. The Company operates through three segments: Pittsburgh, Birmingham, and Eagan. Pittsburgh segment provides services, which include the application of artificial intelligence (AI) using its proprietary biobank of 150,000 plus tumor samples. Pittsburgh segment also develops tumor-specific in vitro models for oncology drug discovery and research. Birmingham segment focuses on contract services and research for biopharmaceutical company clients and academic collaborators, focused on solubility improvements, stability studies, and protein production. Specifically, Birmingham provides optimized formulations for vaccines, antibodies, and other protein therapeutics. Eagan segment produces the STREAMWAY System and associated products for automated medical fluid waste management and patient-to-drain medical fluid disposal.
Growing
The company is in a growing phase, with the latest annual income totaling USD 1.62M.
Undervalued
The company’s latest PE is -0.86, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 299.51K shares, decreasing 49.08% quarter-over-quarter.
Held by The Vanguard
Star Investor The Vanguard holds 71.31K shares of this stock.

News

More news coming soon, stay tuned...

Financial Indicators

EPS

No Data

Total revenue

No Data

Company

Predictive Oncology Inc. is a knowledge-driven company focused on applying artificial intelligence (AI) to support the development of cancer therapies. The Company operates through three segments: Pittsburgh, Birmingham, and Eagan. Pittsburgh segment provides services, which include the application of artificial intelligence (AI) using its proprietary biobank of 150,000 plus tumor samples. Pittsburgh segment also develops tumor-specific in vitro models for oncology drug discovery and research. Birmingham segment focuses on contract services and research for biopharmaceutical company clients and academic collaborators, focused on solubility improvements, stability studies, and protein production. Specifically, Birmingham provides optimized formulations for vaccines, antibodies, and other protein therapeutics. Eagan segment produces the STREAMWAY System and associated products for automated medical fluid waste management and patient-to-drain medical fluid disposal.
Ticker SymbolPOAI
CompanyPredictive Oncology Inc
CEOMr. Raymond F. Vennare
Websitehttps://predictive-oncology.com/
KeyAI